IMPORTANT INFORMATION
This satellite symposium will be offered both In-Person and Virtually.
THIS SESSION IS TAKING PLACE AT THE 18th ST. GALLEN INTERNATIONAL BREAST CANCER CONFERENCE 2023 IN VIENNA, AUSTRIA.
PLEASE NOTE: Only registered attendees of the 18th St. Gallen International Breast Cancer Conference 2023 can attend this session in-person or virtually.
OVERVIEW
Therapy options are rapidly expanding for patients with HR–positive, HER2-negative, node-positive, high-risk early breast cancer. Data presented at the 2022 European Society of Medical Oncologists (ESMO) and the 2022 San Antonio Breast Cancer Symposium (SABCS) showed continued benefit using novel therapies for treatment in the adjuvant setting. How will these findings be applied in the clinic? Join Dr Sara Tolaney and Dr Giuseppe Curigliano for a multi-faceted case review that brings the latest treatment guidelines, study data, and patient management information into the exam room and applies it to individualized treatment decision-making for patients with HR-positive, HER2-negative early breast cancer.
GOAL STATEMENT
The goal of this activity is for learners to be better able to individualize adjuvant therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) by appropriately identifying patients at high risk of recurrence and selecting optimal therapies based on the latest scientific data, guideline recommendations, and control of adverse events (AEs).
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have greater competence related to applying the [LIST][ITEM]Eligibility criteria for patients at high risk of recurrence for adjuvant treatment based on patient characteristics[ITEM]Treatment recommendations for adjuvant therapy in patients with HR-positive, HER2-negative EBC at high risk of recurrence[ITEM]Recommendations for managing AEs associated with adjuvant therapy[/LIST] Demonstrate greater confidence in their ability to [LIST][ITEM]Communicate and counsel patients about the potential treatment-related adverse events associated with adjuvant therapies to improve adherence[/LIST]
ACCREDITATION STATEMENT
[JALOGO][MEDSCAPE] In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 0.75 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [BOLD]For Nurses[/BOLD] Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs.
Austria Center Vienna - Room: Auditorium
Bruno-Kreisky-Platz 1
1220 Vienna
Austria
Supported by an independent educational grant from Lilly.